Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome

NCT07704047 is registered in ClinicalTrials.gov with Chongqing Peg-Bio Biopharm Co., Ltd. as lead sponsor.

NCT NCT07704047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07704047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome
Lead sponsor
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 30, 2026
Completion date
April 15, 2027
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sbs, short bowel syndrome